2020 Korean guidelines for the management of metastatic prostate cancer

In Ho Kim; Sang Joon Shin; Byung Woog Kang; Jihoon Kang; Dalyong Kim; Miso Kim; Jin Young Kim; Chan Kyu Kim; Hee Jun Kim; Chi Hoon Maeng; Kwonoh Park; Inkeun Park; Woo Kyun Bae; Byeong Seok Sohn; Min Young Lee; Jae Lyun Lee; Junglim Lee; Seung Taek Lim; Joo Han Lim; Hyun Chang; Joo Young Jung; Yoon Ji Choi; Young Seok Kim; Jaeho Cho; Jae Young Joung; Se Hoon Park; Hyo Jin Lee

doi:10.3904/kjim.2020.213

2020 Korean guidelines for the management of metastatic prostate cancer

In Ho Kim, Sang Joon Shin, Byung Woog Kang, Jihoon Kang, Dalyong Kim, Miso Kim, Jin Young Kim, Chan Kyu Kim, Hee Jun Kim, Chi Hoon Maeng, Kwonoh Park, Inkeun Park, Woo Kyun Bae, Byeong Seok Sohn, Min Young Lee, Jae Lyun Lee, Junglim Lee, Seung Taek Lim, Joo Han Lim, Hyun ChangJoo Young Jung, Yoon Ji Choi, Young Seok Kim, Jaeho Cho, Jae Young Joung, Se Hoon Park, Hyo Jin Lee

Department of Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: Management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.

Original language	English
Pages (from-to)	491-514
Number of pages	24
Journal	Korean Journal of Internal Medicine
Volume	36
Issue number	3
DOIs	https://doi.org/10.3904/kjim.2020.213
Publication status	Published - 2021 May

Bibliographical note

Funding Information:
This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/ Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee’s contributions span from the publication of the first version of this guideline, to the present 2nd edition.

Funding Information:
This study was supported by a grant from the National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee’s contributions span from the publication of the first version of this guideline, to the present 2nd edition.

Publisher Copyright:
© 2021 The Korean Association of Internal Medicine.

All Science Journal Classification (ASJC) codes

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3904/kjim.2020.213

Cite this

Kim, I. H., Shin, S. J., Kang, B. W., Kang, J., Kim, D., Kim, M., Kim, J. Y., Kim, C. K., Kim, H. J., Maeng, C. H., Park, K., Park, I., Bae, W. K., Sohn, B. S., Lee, M. Y., Lee, J. L., Lee, J., Lim, S. T., Lim, J. H., ... Lee, H. J. (2021). 2020 Korean guidelines for the management of metastatic prostate cancer. Korean Journal of Internal Medicine, 36(3), 491-514. https://doi.org/10.3904/kjim.2020.213

@article{d8c32dfd036a4ba28c4aa53ff5751d56,

title = "2020 Korean guidelines for the management of metastatic prostate cancer",

abstract = "In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: Management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.",

author = "Kim, {In Ho} and Shin, {Sang Joon} and Kang, {Byung Woog} and Jihoon Kang and Dalyong Kim and Miso Kim and Kim, {Jin Young} and Kim, {Chan Kyu} and Kim, {Hee Jun} and Maeng, {Chi Hoon} and Kwonoh Park and Inkeun Park and Bae, {Woo Kyun} and Sohn, {Byeong Seok} and Lee, {Min Young} and Lee, {Jae Lyun} and Junglim Lee and Lim, {Seung Taek} and Lim, {Joo Han} and Hyun Chang and Jung, {Joo Young} and Choi, {Yoon Ji} and Kim, {Young Seok} and Jaeho Cho and Joung, {Jae Young} and Park, {Se Hoon} and Lee, {Hyo Jin}",

note = "Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/ Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee{\textquoteright}s contributions span from the publication of the first version of this guideline, to the present 2nd edition. Funding Information: This study was supported by a grant from the National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee{\textquoteright}s contributions span from the publication of the first version of this guideline, to the present 2nd edition. Publisher Copyright: {\textcopyright} 2021 The Korean Association of Internal Medicine.",

year = "2021",

month = may,

doi = "10.3904/kjim.2020.213",

language = "English",

volume = "36",

pages = "491--514",

journal = "Korean Journal of Internal Medicine",

issn = "1226-3303",

publisher = "Korean Association of Internal Medicine",

number = "3",

}

Kim, IH, Shin, SJ, Kang, BW, Kang, J, Kim, D, Kim, M, Kim, JY, Kim, CK, Kim, HJ, Maeng, CH, Park, K, Park, I, Bae, WK, Sohn, BS, Lee, MY, Lee, JL, Lee, J, Lim, ST, Lim, JH, Chang, H, Jung, JY, Choi, YJ, Kim, YS, Cho, J, Joung, JY, Park, SH & Lee, HJ 2021, '2020 Korean guidelines for the management of metastatic prostate cancer', Korean Journal of Internal Medicine, vol. 36, no. 3, pp. 491-514. https://doi.org/10.3904/kjim.2020.213

TY - JOUR

T1 - 2020 Korean guidelines for the management of metastatic prostate cancer

AU - Kim, In Ho

AU - Shin, Sang Joon

AU - Kang, Byung Woog

AU - Kang, Jihoon

AU - Kim, Dalyong

AU - Kim, Miso

AU - Kim, Jin Young

AU - Kim, Chan Kyu

AU - Kim, Hee Jun

AU - Maeng, Chi Hoon

AU - Park, Kwonoh

AU - Park, Inkeun

AU - Bae, Woo Kyun

AU - Sohn, Byeong Seok

AU - Lee, Min Young

AU - Lee, Jae Lyun

AU - Lee, Junglim

AU - Lim, Seung Taek

AU - Lim, Joo Han

AU - Chang, Hyun

AU - Jung, Joo Young

AU - Choi, Yoon Ji

AU - Kim, Young Seok

AU - Cho, Jaeho

AU - Joung, Jae Young

AU - Park, Se Hoon

AU - Lee, Hyo Jin

N1 - Funding Information: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/ Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee’s contributions span from the publication of the first version of this guideline, to the present 2nd edition. Funding Information: This study was supported by a grant from the National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150). The present guideline was prepared by the Korean Society of Medical Oncology (KSMO)/Korean Cancer Study Group (KCSG). We would like to express our sincere thanks to all the committee members of this guideline development. And we would like to express gratitude to Professor Jae Lyun Lee, who is the chairman of the genitourinary/gynecological cancer committee of KCSG. Professor Jae Lyun Lee’s contributions span from the publication of the first version of this guideline, to the present 2nd edition. Publisher Copyright: © 2021 The Korean Association of Internal Medicine.

PY - 2021/5

Y1 - 2021/5

N2 - In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: Management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.

AB - In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: Management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.

UR - http://www.scopus.com/inward/record.url?scp=85107083984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107083984&partnerID=8YFLogxK

U2 - 10.3904/kjim.2020.213

DO - 10.3904/kjim.2020.213

M3 - Review article

C2 - 33561334

AN - SCOPUS:85107083984

SN - 1226-3303

VL - 36

SP - 491

EP - 514

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

IS - 3

ER -

2020 Korean guidelines for the management of metastatic prostate cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this